Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07114666) titled 'XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer' on Aug. 3.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Peking Union Medical College Hospital
Condition:
Pancreatic Cancer
Intervention:
Biological: XH001
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: August 18, 2025
Target Sample Size: 12
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07114666
...